Syndax Pharmaceuticals Inc 8-K

What Happened

• Syndax Pharmaceuticals, Inc. (SNDX) filed a Form 8-K on February 26, 2026 (Item 2.02) announcing that it issued a press release and corporate presentation with its financial results for the quarter and full year ended December 31, 2025. The press release and presentation are furnished as Exhibits 99.1 and 99.2 to the filing and are incorporated by reference.

Key Details

• Filing date: February 26, 2026.
• Reporting period: Quarter and year ended December 31, 2025.
• Documents furnished: Exhibit 99.1 (Press Release, dated Feb 26, 2026) and Exhibit 99.2 (Corporate Presentation, dated Feb 26, 2026).
• Filing signed by Michael A. Metzger, Chief Executive Officer, on behalf of Syndax Pharmaceuticals.

Why It Matters

• The 8-K signals that Syndax has publicly released its recent earnings and financial condition; investors should review the attached press release and presentation for revenue, expenses, net income/loss, cash position, and any updated guidance or commentary. Earnings and year‑end results can affect investor expectations, valuation, and near-term trading, so checking the exhibits is the next step for specific figures and management commentary.